The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden
Abstract
Immune effector cells, including T cells and natural killer cells, which are genetically engineered to express a chimeric antigen receptor (CAR), constitute a powerful new class of therapeutic agents to treat patients with hematologic malignancies. Several CAR T-cell trials have shown impressive remission rates in patients with relapsed/refractory hematologic cancers. Although the clinical responses of these agents in hematologic malignancies have been very encouraging, they have also produced substantial morbidity and occasionally mortality resulting from toxicity. With more experience and collaboration, hopefully the toxicities and the costs will come down, increasing the availability of CAR T cells to patients in need.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Self-citationChimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688
Self-citationAdoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Self-citationChimeric Antigen Receptor Therapy
June, C. H., & Sadelain, M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706169 · Cited by 2,331
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Gross, G., Waks, T., & Eshhar, Z. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10024 · Cited by 1,590
The Basic Principles of Chimeric Antigen Receptor Design
Sadelain, M., Brentjens, R., & Rivière, I. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0548 · Cited by 1,535
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406
Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156
Gardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor
Maher, J., Brentjens, R. J., Gunset, G., Rivière, I., & Sadelain, M. (2002) · Nature Biotechnology · doi:10.1038/nbt0102-70 · Cited by 1,034
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016
Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1319 · Cited by 942
Self-citationRecent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Brudno, J. N., & Kochenderfer, J. N. (2019) · Blood Reviews · doi:10.1016/j.blre.2018.11.002 · Cited by 899
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008) · Blood · doi:10.1182/blood-2008-05-155846 · Cited by 795
Brudno, J. N., Maric, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler-Stevenson, M., Salem, D., Yuan, C., Pavletic, S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 781
Ali, S. A., Shi, V., Maric, I., Wang, M., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler-Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 757
TRUCKs: the fourth generation of CARs
Chmielewski, M., & Abken, H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1046430 · Cited by 738
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 652
Kochenderfer, J. N., Somerville, R. P. T., Lu, T., Shi, V., Bot, A., Rossi, J., Xue, A., Goff, S. L., Yang, J. C., Sherry, R. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3024 · Cited by 569
The determination and interpretation of the therapeutic index in drug development
Muller, P. Y., & Milton, M. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3801 · Cited by 563
Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487
Finney, H. M., Akbar, A. N., & Lawson, A. D. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.104 · Cited by 467
Hay, K. A., Gauthier, J., Hirayama, A. V., Voutsinas, J. M., Wu, Q., Li, D., Gooley, T. A., Cherian, S., Chen, X., Pender, B. S., et al. (2019) · Blood · doi:10.1182/blood-2018-11-883710 · Cited by 404
Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
Porter, D., Frey, N., Wood, P. A., Weng, Y., & Grupp, S. A. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0571-y · Cited by 401
Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling.
Rudd, C. E., & Schneider, H. (2003) · Nature Reviews Immunology · doi:10.1038/nri1131 · Cited by 392
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Gill, S., & June, C. H. (2015) · Immunological Reviews · doi:10.1111/imr.12243 · Cited by 320
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
Wang, Z., & Han, W. (2018) · Biomarker Research · doi:10.1186/s40364-018-0116-0 · Cited by 273
Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
Taraseviciute, A., Tkachev, V., Ponce, R., Turtle, C. J., Snyder, J. M., Liggitt, H. D., Myerson, D., Gonzalez-Cuyar, L., Baldessari, A., English, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1368 · Cited by 256
Siltuximab, a Novel Anti–Interleukin-6 Monoclonal Antibody, for Castleman's Disease
van Rhee, F., Fayad, L., Voorhees, P., Furman, R., Lonial, S., Borghaei, H., Sokol, L., Crawford, J., Cornfeld, M., Qi, M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2377 · Cited by 243
Biffi, A., Bartolomae, C. C., Cesana, D., Cartier, N., Aubourg, P., Ranzani, M., Cesani, M., Benedicenti, F., Plati, T., Rubagotti, E., et al. (2011) · Blood · doi:10.1182/blood-2010-09-306761 · Cited by 216
Kawalekar, O. U., O’ Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.023 · Cited by 196
Chen, F., Teachey, D. T., Pequignot, E., Frey, N., Porter, D., Maude, S. L., Grupp, S. A., June, C. H., Melenhorst, J. J., & Lacey, S. F. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.03.005 · Cited by 195
Hu, Y., Sun, J., Wu, Z., Yu, J., Cui, Q., Pu, C., Liang, B., Luo, Y., Shi, J., Jin, A., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0299-5 · Cited by 178
4-1BB enhancement of CAR T function requires NF-κB and TRAFs
Li, G., Boucher, J. C., Kotani, H., Park, K., Zhang, Y., Shrestha, B., Wang, X., Guan, L., Beatty, N. J., Abate‐Daga, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121322 · Cited by 167
Hay, K. A., & Turtle, C. J. (2017) · Drugs · doi:10.1007/s40265-017-0690-8 · Cited by 145
Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema
Torre, M., Solomon, I. H., Sutherland, C. L., Nikiforow, S., DeAngelo, D. J., Stone, R. M., Vaitkevicius, H., Galinsky, I. A., Padera, R. F., Trede, N. S., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly064 · Cited by 132
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Teachey, D. T., Bishop, M. R., Maloney, D. G., & Grupp, S. A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.19 · Cited by 121
Hypogammaglobulinemia due to CAR T‐cell therapy
Doan, A., & Pulsipher, M. A. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26914 · Cited by 99
CAR T-Cell Therapy: Progress and Prospects
Wilkins, O., Keeler, A. M., & Flotte, T. R. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.153 · Cited by 68
Gardner, R., Leger, K. J., Annesley, C., Summers, C. N., Rivers, J. M., Gust, J., Tarlock, K., Cooper, T. M., Pinto, N. R., Finney, O. C., et al. (2016) · Blood · doi:10.1182/blood.v128.22.586.586 · Cited by 65
The why, what, and how of the new FACT standards for immune effector cells
Maus, M. V., & Nikiforow, S. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0239-0 · Cited by 59
Riët, T., Holzinger, A., Dörrie, J., Schaft, N., Schuler, G., & Abken, H. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_12 · Cited by 49
Shah, B. D., Huynh, V., Sender, L. S., Lee, D. W., Castro, J. E., Wierda, W. G., Dietz, A. C., Schiller, G. J., Kersten, M. J., Handgretinger, R., et al. (2016) · Blood · doi:10.1182/blood.v128.22.2803.2803 · Cited by 29
Cited by
Targeted drug delivery strategies for precision medicines
Manzari, M. T., Shamay, Y., Kiguchi, H., Rosen, N., Scaltriti, M., & Heller, D. A. (2021) · Nature Reviews Materials · doi:10.1038/s41578-020-00269-6 · Cited by 1,183
The cancer–natural killer cell immunity cycle
Huntington, N. D., Cursons, J., & Rautela, J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0272-z · Cited by 566
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
Schubert, M.-L., Schmitt, M., Wang, L., Ramos, C. A., Jordan, K., Müller-Tidow, C., & Dreger, P. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.10.478 · Cited by 491
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
Smith, M., Dai, A., Ghilardi, G., Amelsberg, K. V., Devlin, S. M., Pajarillo, R., Slingerland, J. B., Beghi, S., Herrera, P. S., Giardina, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01702-9 · Cited by 349
Xiao, X., Huang, S., Chen, S., Wang, Y., Sun, Q., Xu, X., & Li, Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02148-6 · Cited by 310
Metadata
- Authors
- Santomasso, B., Bachier, C., Westin, J., Rezvani, K., & Shpall, E. J.
- Venue
- American Society of Clinical Oncology Educational Book
- Published
- 2019-05
- Volume
- 39
- Issue
- 39
- Pages
- 433-444
- ISSN
- 1548-8748 (ISSN-L)
- 1548-8756
- OpenAlex
- W2944998775
- Cited by
- 330
- References
- 63
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.